390 related articles for article (PubMed ID: 28836745)
1. Use of Biologics and Biosimilars in Rheumatology.
Sharma SK
J Assoc Physicians India; 2017 May; 65(5 Suppl):9-14. PubMed ID: 28836745
[TBL] [Abstract][Full Text] [Related]
2. Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology.
Mysler E; Pineda C; Horiuchi T; Singh E; Mahgoub E; Coindreau J; Jacobs I
Rheumatol Int; 2016 May; 36(5):613-25. PubMed ID: 26920148
[TBL] [Abstract][Full Text] [Related]
3. Biosimilars: A Multidisciplinary Perspective.
Khraishi M; Stead D; Lukas M; Scotte F; Schmid H
Clin Ther; 2016 May; 38(5):1238-49. PubMed ID: 26988243
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor necrosis factor biosimilars and intended copies in rheumatology: Perspective from the Asia Pacific region.
Rath PD; Chen DY; Gu J; Lee VWY; Al Ani NA; Shirazy K; Llamado L
Int J Rheum Dis; 2019 Jan; 22(1):9-24. PubMed ID: 30338644
[TBL] [Abstract][Full Text] [Related]
5. Biosimilars in Rheumatology- Name Changers or Game Changers?
Handa R
J Assoc Physicians India; 2017 May; 65(5 Suppl):6-8. PubMed ID: 28836744
[No Abstract] [Full Text] [Related]
6. Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm.
Schulze-Koops H; Skapenko A
Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv30-iv48. PubMed ID: 28903543
[TBL] [Abstract][Full Text] [Related]
7. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.
Crespi-Lofton J; Skelton JB
J Am Pharm Assoc (2003); 2017; 57(5):e15-e27. PubMed ID: 28689708
[TBL] [Abstract][Full Text] [Related]
8. The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis.
Yoo DH
Expert Rev Clin Immunol; 2014 Aug; 10(8):981-3. PubMed ID: 24961712
[TBL] [Abstract][Full Text] [Related]
9. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
[TBL] [Abstract][Full Text] [Related]
10. Biosimilars in inflammatory bowel disease.
Gargallo CJ; Lué A; Gomollón F
Minerva Med; 2017 Jun; 108(3):239-254. PubMed ID: 28176515
[TBL] [Abstract][Full Text] [Related]
11. The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects.
Declerck P; Danesi R; Petersel D; Jacobs I
Drugs; 2017 Apr; 77(6):671-677. PubMed ID: 28258517
[TBL] [Abstract][Full Text] [Related]
12. Is it time for biosimilars in autoimmune diseases?
Cuadrado MJ; Sciascia S; Bosch X; Khamashta MA; Ramos-Casals M
Autoimmun Rev; 2013 Aug; 12(10):954-7. PubMed ID: 23542505
[TBL] [Abstract][Full Text] [Related]
13. Practical Guidance on Biosimilars, With a Focus on Latin America: What Do Rheumatologists Need to Know?
Azevedo VF; Babini A; Caballero-Uribe CV; Castañeda-Hernández G; Borlenghi C; Jones HE
J Clin Rheumatol; 2019 Mar; 25(2):91-100. PubMed ID: 30059414
[TBL] [Abstract][Full Text] [Related]
14. Biosimilars and drug development in allergic and immunologic diseases.
Bonini S; Bonini M
J Allergy Clin Immunol; 2017 May; 139(5):1461-1464. PubMed ID: 28359671
[No Abstract] [Full Text] [Related]
15. Biosimilars in rheumatology: pharmacological and pharmacoeconomic issues.
Lapadula G; Ferraccioli GF
Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S102-6. PubMed ID: 23078880
[TBL] [Abstract][Full Text] [Related]
16. Biosimilars in rheumatology: understanding the rigor of their development.
Goel N; Chance K
Rheumatology (Oxford); 2017 Feb; 56(2):187-197. PubMed ID: 27241704
[TBL] [Abstract][Full Text] [Related]
17. Switching to biosimilars in the treatment of rheumatic diseases.
Yoo DH; Choe JY; Shim SC; Suh CH
Expert Rev Clin Immunol; 2018 Jul; 14(7):557-571. PubMed ID: 29914272
[TBL] [Abstract][Full Text] [Related]
18. Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe.
Müller-Ladner U; Hong S; Oh C; Taylor P
Expert Rev Clin Immunol; 2015; 11 Suppl 1():S5-14. PubMed ID: 26395832
[TBL] [Abstract][Full Text] [Related]
19. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.
Ingrasciotta Y; Cutroneo PM; Marcianò I; Giezen T; Atzeni F; Trifirò G
Drug Saf; 2018 Nov; 41(11):1013-1022. PubMed ID: 29796832
[TBL] [Abstract][Full Text] [Related]
20. Biosimilars in rheumatology: recommendations for regulation and use in Middle Eastern countries.
El Zorkany B; Al Ani N; Al Emadi S; Al Saleh J; Uthman I; El Dershaby Y; Mounir M; Al Moallim H
Clin Rheumatol; 2018 May; 37(5):1143-1152. PubMed ID: 29411181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
